Sugi Predict

Sugi Predict / Targets / PSENEN

PSENEN

Gamma-secretase subunit PEN-2 · Q9NZ42 · PSENEN on Sugi Atlas →

142,888 patent compounds predicted against PSENEN, 75,274 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL33171 SCHEMBL33171 1.00 20/20
SCHEMBL137789 SCHEMBL137789 1.00 20/20
SCHEMBL139302 SCHEMBL139302 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237758) 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237759) 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237760) 1.00 20/20
SCHEMBL136503 SCHEMBL136503 0.76 20/20
SCHEMBL154957 SCHEMBL154957 0.66 20/20
SCHEMBL138898 SCHEMBL138898 0.66 20/20
SCHEMBL139605 SCHEMBL139605 0.66 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL154119) 0.65 20/20
SCHEMBL139065 SCHEMBL139065 0.64 20/20
SCHEMBL151407 SCHEMBL151407 0.62 20/20
SCHEMBL138968 SCHEMBL138968 0.61 20/20
SCHEMBL139498 SCHEMBL139498 0.60 20/20
SCHEMBL154717 SCHEMBL154717 0.58 20/20
SCHEMBL139470 SCHEMBL139470 0.58 20/20
SCHEMBL139515 SCHEMBL139515 0.58 20/20
SCHEMBL139460 SCHEMBL139460 0.58 20/20
SCHEMBL155625 SCHEMBL155625 0.57 20/20

Clinical trials — most relevant to PSENEN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. PHASE2/PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 PHASE2/PHASE3ACTIVE_NOT_RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
Development of NIC5-15 in the Treatment of Alzheimer's Disease PHASE2COMPLETED
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease PHASE2COMPLETED
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) PHASE2COMPLETED
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort PHASE2COMPLETED
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma PHASE1/PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE2COMPLETED
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB PHASE2COMPLETED
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) PHASE1COMPLETED
Phenserine on the Alzheimer's Treatment Horizon, Study 1 PHASE1COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma PHASE1COMPLETED
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors PHASE1COMPLETED
Exploratory and Safety Study of [F-18]W372 EARLY_PHASE1COMPLETED
Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome nanUNKNOWN
Late Onset Alzheimer's Disease nanRECRUITING
P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid nanCOMPLETED
The Genetic Characterization of Dementia nanCOMPLETED
Apolipoprotein E Gene and Functional MRI nanCOMPLETED
Dominantly Inherited Alzheimer Network (DIAN) nanRECRUITING
Central and Systemic Inflammation in Alzheimer's Disease nanCOMPLETED
Bace1as Role in Heart Failure (BACE1AS-HF) nanCOMPLETED
Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers. nanCOMPLETED
China Cognition and Aging Study nanRECRUITING
The Evaluation and Follow-up of Individuals With Memory Disorder nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSENEN binder may also engage these)

ProteinNameSimilarity
Q9CQR7 — 1.000 Q9CQR7 →
Q5G235 — 1.000 Q5G235 →
Q6QI68 — 1.000 Q6QI68 →
Q8JHF0 — 1.000 Q8JHF0 →
Q9SKT3 — 0.968 Q9SKT3 →
F4I8Q7 — 0.967 F4I8Q7 →
Q75D26 — 0.966 Q75D26 →
Q9FY84 — 0.965 Q9FY84 →
Q86BE9 — 0.964 Q86BE9 →
Q6PDU4 — 0.964 Q6PDU4 →
A0A078H868 — 0.964 A0A078H868 →
Q7ZXH1 — 0.963 Q7ZXH1 →
O15243 — 0.963 O15243 →
Q9M5P2 — 0.962 Q9M5P2 →
Q3ZBX1 — 0.962 Q3ZBX1 →
Q9ZTX0 — 0.962 Q9ZTX0 →
Q7F613 — 0.962 Q7F613 →
Q5XF36 — 0.962 Q5XF36 →
Q9D1X9 — 0.962 Q9D1X9 →
Q9FJB4 — 0.962 Q9FJB4 →
Q3SYT0 — 0.962 Q3SYT0 →
Q9CXR4 — 0.962 Q9CXR4 →
O77761 — 0.961 O77761 →
O89013 — 0.961 O89013 →
Q60457 — 0.961 Q60457 →
Q5TYP8 — 0.961 Q5TYP8 →
O95807 — 0.961 O95807 →
A2VDC7 — 0.961 A2VDC7 →
Q6IQ85 — 0.961 Q6IQ85 →
B9TRX0 — 0.961 B9TRX0 →